NCT04409314
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +33 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States
Clinical trial condition
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Explore clinical trials studying Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma. Study availability and eligibility vary by location and protocol.
4 public trials
0 recruiting studies
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma trial results
Active, Not Recruiting
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT04007029
- Conditions
- CD19 Positive, CD20 Positive, Chronic Disease, +33 more
- Locations
-
- UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
Active, Not Recruiting
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
NCT03150329
- Conditions
- Grade 3b Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +25 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Active, Not Recruiting
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04665765
- Conditions
- Diffuse Large B-Cell Lymphoma Unclassifiable, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Emory University Atlanta, Georgia, United States